November 16, 2026

HPA-Global strategic regulatory partner CIRS Group has announced the successful completion of a U.S. Food and Drug Administration (FDA) New Dietary Ingredient Notification (NDIN) for β-nicotinamide mononucleotide (NMN) produced by Shenzhen Siyomicro Biotech Co., Ltd., a Chinese synthetic biology company.
According to CIRS, the ingredient received an FDA no-objection response under NDIN No. 1495, representing an important regulatory milestone for the company’s efforts to enter the U.S. dietary supplement market.
CIRS provided regulatory support throughout the project, including preparation of the notification dossier and assistance during the FDA review process. The company reported that the entire project, from initiation to receipt of the FDA response, was completed in less than five months.
NMN is a naturally occurring nucleotide and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy metabolism and numerous biological processes. The ingredient has attracted substantial commercial and scientific interest in the healthy aging and cellular health markets.
The development is particularly noteworthy given NMN’s complicated regulatory history in the United States. In 2022, FDA determined that NMN was excluded from the definition of a dietary supplement because of its investigation as a potential pharmaceutical ingredient.
However, in September 2025, FDA reversed that position, concluding that NMN was not excluded from the dietary supplement definition because evidence established that it had been marketed as a dietary supplement before authorization for investigation as a drug.
The regulatory reversal created renewed opportunities for ingredient manufacturers seeking to establish compliant pathways into the U.S. dietary supplement market.
Under the NDI notification process, companies submit information supporting the identity and safety of new dietary ingredients under their intended conditions of use. An FDA no-objection response indicates that the agency did not identify grounds for objection during its review, but it does not constitute formal FDA approval or authorization of health claims.
Siyomicro specializes in synthetic biology and has developed technology platforms combining computational biology, high-throughput screening, and automated strain development. Its ingredient portfolio also includes ergothioneine, ectoine, and superoxide dismutase (SOD).
What This Means for the Industry
This development highlights the growing ability of Chinese synthetic biology companies to navigate international regulatory requirements and bring innovative nutritional ingredients to overseas markets.
For manufacturers and distributors interested in NMN, the successful notification represents another development in establishing regulatory pathways for specific NMN ingredients in the United States.
Importantly, an FDA no-objection response applies to the specific ingredient and intended conditions of use described in the notification. It should not be interpreted as blanket authorization for all NMN products or manufacturing processes.
The project also demonstrates the international regulatory capabilities of HPA-Global strategic partner CIRS Group, which supports companies with U.S. NDI notifications, GRAS assessments, EU Novel Food applications, China new food ingredient approvals, and other regulatory requirements across major international markets.
For nutritional ingredient companies pursuing international commercialization, early regulatory planning, comprehensive safety documentation, and experienced technical support remain essential components of successful market entry.
Sources:
- CIRS Group – CIRS Assists Siyomicro in Securing U.S. FDA NDI Notification for NMN, November 16, 2026
- American Herbal Products Association – FDA Reverses NMN Exclusion Determination, October 1, 2025
- U.S. FDA – New Dietary Ingredient Notification Process
HPA-Global works closely with strategic regulatory partner CIRS Group to support dietary supplement and nutritional ingredient companies with regulatory consulting, product compliance, ingredient notifications, and market-entry strategies across China, the United States, Europe, Japan, South Korea, and other international markets.
For more details, visit www.hpaglobal.org/connect.